Growth Metrics

Sonoma Pharmaceuticals (SNOA) Long-Term Debt Repayments (2016 - 2022)

Sonoma Pharmaceuticals has reported Long-Term Debt Repayments over the past 13 years, most recently at -$340000.0 for Q4 2022.

  • For Q4 2022, Long-Term Debt Repayments fell 270.85% year-over-year to -$340000.0; the TTM value through Mar 2024 reached -$906000.0, down 28.15%, while the annual FY2023 figure was $120000.0, 300.0% up from the prior year.
  • Long-Term Debt Repayments for Q4 2022 was -$340000.0 at Sonoma Pharmaceuticals, up from -$566000.0 in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $321000.0 in Q1 2020 and troughed at -$566000.0 in Q1 2022.
  • A 5-year average of $50352.9 and a median of $105000.0 in 2019 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 791.67% in 2020 and later plummeted 270.85% in 2022.
  • Year by year, Long-Term Debt Repayments stood at $216000.0 in 2018, then plummeted by 199.54% to -$215000.0 in 2019, then surged by 122.79% to $49000.0 in 2020, then soared by 306.12% to $199000.0 in 2021, then plummeted by 270.85% to -$340000.0 in 2022.
  • Business Quant data shows Long-Term Debt Repayments for SNOA at -$340000.0 in Q4 2022, -$566000.0 in Q1 2022, and $199000.0 in Q4 2021.